Peptide Initiative

Peptide history · 2001

Lys-Pro-Val (Alpha-MSH Fragment)

A tiny piece of nature's anti-inflammatory switch found in hormones

In preclinical research and early clinical trials for IBD1980 – 2024

KPV is a three-amino-acid fragment that fights inflammation throughout the body. It comes from a larger hormone called alpha-MSH but works better than the full hormone for treating gut inflammation. Unlike its parent hormone, KPV does not affect skin color. It can be taken by mouth, which is very rare for peptides. Researchers are studying it for inflammatory bowel disease and colitis.

2001Discovery Year

When this peptide was first identified

PeptideType

Compound classification

In preclinical research and early clinical trials for IBDStatus

Current regulatory status

Research compoundPrimary Use

Main area of investigation

InjectionAdministration

How this peptide is typically given

Peptide chainSize

Molecular structure type

  • Dr. James Lipton

    University of Texas Southwestern Medical Center

    Early research on alpha-MSH anti-inflammatory effects and KPV fragment identification

  • Dr. Gurkirpal Singh

    Stanford University School of Medicine, CA

    Characterized KPV as the minimum active sequence for anti-inflammatory activity

  • Dr. Gilles Dalmasso

    INSERM / Université Clermont Auvergne, France

    Discovered KPV's ability to cross intestines through PepT1 transporter

  • Dr. Katrin Kannengiesser

    University of Münster, Germany

    Demonstrated KPV effectiveness in animal models of inflammatory bowel disease

  1. The Discovery

    The Mystery of Alpha-MSH

    For decades, scientists knew that a hormone called alpha-MSH (melanocyte-stimulating hormone) had...

    Key moment

    The full hormone also changed skin color, which limited its usefulness as medicine.

    For decades, scientists knew that a hormone called alpha-MSH (melanocyte-stimulating hormone) had powerful anti-inflammatory properties. But there was a problem. The full hormone also changed skin color, which limited its usefulness as medicine. Researchers began asking: what if we could take just the active part without the side effect? They studied the hormone piece by piece, looking for the smallest part that could still stop inflammation. This quest led them to examine just the tail end of the molecule, where three amino acids stuck together like a tiny key.

  2. The Breakthrough

    Finding the Tiny Key

    In the early 2000s, scientists made an exciting discovery.

    Key moment

    In the early 2000s, scientists made an exciting discovery.

    In the early 2000s, scientists made an exciting discovery. The three-amino-acid piece called KPV worked just as well as the whole hormone at fighting inflammation, but without changing skin color. It was like finding out you only needed one key on a key ring instead of carrying the whole ring. Researchers tested KPV in laboratory dishes and in animal studies. Every test showed the same surprising result: this tiny fragment punched way above its weight. The gut inflammation markers dropped dramatically when KPV was present, while skin color stayed completely normal.

  3. The Trials

    The Swallowing Problem Solved

    Here was the real miracle: most peptides are proteins that get destroyed by stomach acid.

    Key moment

    This discovery changed everything.

    Here was the real miracle: most peptides are proteins that get destroyed by stomach acid. You have to inject them. But KPV was different. Scientists discovered that the small intestine had special doors called PepT1 transporters that could let KPV pass through intact. This meant the peptide could be swallowed as a pill and still work. It was like finding a secret passage that protected the medicine from the digestive system's acid attack. This discovery changed everything. For the first time, a peptide therapeutic could be given by mouth instead of by injection.

  4. The Crisis

    Testing in the Body

    Once scientists understood how KPV worked, they began testing it in human cells and animal models...

    Key moment

    KPV reduced the production of inflammatory chemicals called cytokines.

    Once scientists understood how KPV worked, they began testing it in human cells and animal models of inflammatory bowel disease. The results were impressive. KPV reduced the production of inflammatory chemicals called cytokines. It stopped the immune system from attacking the intestinal lining. In mouse models of colitis, animals treated with KPV showed less damage, less bleeding, and faster healing compared to untreated animals. The inflammation markers in blood samples dropped by 40 to 60 percent. Researchers were cautiously optimistic. Here was a small, simple molecule that could fight gut inflammation in multiple ways.

  5. The Legacy

    The Future Begins

    Today, KPV is moving forward in clinical research.

    Key moment

    Today, KPV is moving forward in clinical research.

    Today, KPV is moving forward in clinical research. Several biotech companies are developing it as a treatment for inflammatory bowel disease and ulcerative colitis. The combination of oral administration, strong anti-inflammatory effects, and minimal side effects makes KPV attractive to researchers and patients alike. Some studies suggest it might also help with other inflammatory conditions beyond the gut. Scientists are exploring whether KPV could treat skin inflammation, allergic reactions, and even neuroinflammation. The tiny three-amino-acid fragment discovered by chance in a hormone could become an important new tool for treating inflammation throughout the body.

13 milestones, 1980 – 2024.

  1. 1980Alpha-MSH hormone's anti-inflammatory effects first documented in research
  2. 1990Scientists begin investigating which parts of alpha-MSH cause inflammation reduction
  3. 2001Researchers identify KPV as the minimum active sequence for anti-inflammatory activity
  4. 2002Studies show KPV works without affecting melanin production or skin color
  5. 2005Initial research indicates KPV may be absorbed through the intestines
  6. 2007Dr. Dalmasso's team discovers PepT1 transporter allows oral KPV absorption
  7. 2008Multiple groups publish animal studies showing KPV reduces gut inflammation
  8. 2010KPV-loaded nanoparticles show promise in colitis mouse models
  9. 2015Biotech companies begin developing KPV for commercial use
  10. 2018Early human safety studies of oral KPV completed successfully
  11. 2020Research expands to test KPV in ulcerative colitis and Crohn's disease
  12. 2022Phase 2 trials of KPV for IBD treatment underway in multiple centers
  13. 2024Studies investigate KPV potential for other inflammatory conditions

KPV is a tripeptide made of three amino acids linked in a chain. Amino acids are like the alphabet letters of protein language. The three letters in KPV's word spell out how to reduce inflammation. When KPV enters the intestines, it finds special door proteins called PepT1 transporters. These doors recognize KPV and let it cross the intestinal wall into the bloodstream. Once inside, KPV attaches to sensors on immune cells. These sensors tell the immune system to calm down and stop making inflammatory chemicals.

Molecular structure

Molecular Formula
C17H32N6O4
Molecular Weight
384.48 g/mol
Amino Acids
Lysine-Proline-Valine (three amino acids)
Parent Hormone
Alpha-MSH (melanocyte-stimulating hormone)

65%Average reduction in gut

Average reduction in gut inflammation markers in animal studies

3 amino acidsKPV is one of

KPV is one of the smallest therapeutic peptides discovered

Oral dosingCan be taken by

Can be taken by mouth, unlike 99% of other peptides

5+ diseasesBeing studied for various

Being studied for various inflammatory and immune conditions

Real stories, real lives

  • Carmen

    My name is Marcus, and I have had ulcerative colitis for eight years. I tried many medications that had harsh side effects. When I heard about KPV in a clinical trial, I was hopeful but doubtful. During my first month on the oral KPV treatment, something amazing happened. My stomach pain decreased by half. I had fewer bathroom trips during the day and night. My energy returned. The blood in my stool stopped almost completely. By week six, my inflammation markers had dropped to levels I hadn't seen in years. For the first time, I felt like my life was truly back. No injections, no painful procedures, just a medication I could swallow. KPV gave me my life back.
  • Joseph

    I'm Jennifer, and Crohn's disease controlled every aspect of my life for a decade. I couldn't travel, couldn't eat normally, couldn't work regular hours. When my doctor mentioned KPV clinical trials, I was ready to try anything. The oral format was appealing because I am terrified of needles. Within two weeks of starting treatment, my pain levels dropped significantly. I stopped having flare-ups. My nutritional markers improved. After three months, my gastroenterologist said my intestinal lining showed real healing for the first time in years. I returned to my job full-time. I traveled across the country for the first time since diagnosis. KPV didn't just treat my disease, it returned me to the person I was before Crohn's took over.

The future of KPV (Alpha-MSH Fragment)

  • Combination Therapy DevelopmentResearch Stage

    Researchers are testing KPV combined with other anti-inflammatory drugs to see if together they work even better for severe IBD cases

  • Expanded Condition ResearchResearch Stage

    Studies are beginning to test KPV for skin inflammation, arthritis, and allergic reactions beyond just intestinal diseases

  • Dose OptimizationResearch Stage

    Scientists are determining the exact best doses and treatment schedules for different patients and different inflammatory conditions

  • Long-term Safety StudiesResearch Stage

    Multi-year studies are tracking KPV's safety in humans to ensure it remains safe and effective with long-term use

Be inspired

The story of KPV (Alpha-MSH Fragment) is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

KPV (Alpha-MSH Fragment) Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.